ArticleMicrobial biotechnology2012
Bacteriophage recombineering in the lytic state using the lambda red recombinases.
Article in Microbial biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 68 citations in OpenAlex.
- Rapid, expression-free bacteriophage-based specific detection of target bacteria by conditional release of encapsidated reporter molecules.Bioengineering & translational medicine · 2026Article
- Rapid detection ofActa biochimica et biophysica Sinica · 2025Article
- Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application.Exploration (Beijing, China) · 2025Article
- Synthetic and Functional Engineering of Bacteriophages: Approaches for Tailored Bactericidal, Diagnostic, and Delivery Platforms.Molecules (Basel, Switzerland) · 2025Review
- Article
- Phage therapy for Klebsiella pneumoniae: Understanding bacteria-phage interactions for therapeutic innovations.PLoS pathogens · 2025Review
- Engineering bacteriophages for targeted superbug eradication.Molecular biology reports · 2025Review
- Data-Driven Engineering of Phages with Tunable Capsule Tropism for Klebsiella pneumoniae.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Review
- T7 phage-assisted evolution of riboswitches using error-prone replication and dual selection.Scientific reports · 2024Article
- Overcoming Bacteriophage Resistance in Phage Therapy.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Synthetic Biology to Engineer Bacteriophage Genomes.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Study of Combined Effect of Bacteriophage vB3530 and Chlorhexidine on the Inactivation of Pseudomonas aeruginosa.BMC microbiology · 2023Article
- The emerging role of recombineering in microbiology.Engineering microbiology · 2023Review
- Genetic Engineering and Biosynthesis Technology: Keys to Unlocking the Chains of Phage Therapy.Viruses · 2023Review
- Efficient traceless modification of the P1 bacteriophage genome through homologous recombination with enrichment in double recombinants: A new perspective on the functional annotation of uncharacterized phage genes.Frontiers in microbiology · 2023Article
- Engineering bacteriophages for enhanced host range and efficacy: insights from bacteriophage-bacteria interactions.Frontiers in microbiology · 2023Review
- Advance on Engineering of Bacteriophages by Synthetic Biology.Infection and drug resistance · 2023Review
- CRISPR-Cas9 Based Bacteriophage Genome Editing.Microbiology spectrum · 2022Article
- Frequency, composition and mobility of Escherichia coli-derived transposable elements in holdings of plasmid repositories.Microbial biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages, the historic model organisms facilitating the initiation of molecular biology, are still important candidates of numerous useful or promising biotechnological applications. Development of generally applicable, simple and rapid techniques for their genetic engineering is therefore a validated goal. In this article, we report the use of bacteriophage recombineering with electroporated DNA (BRED), for the first time in a coliphage. With the help of BRED, we removed a copy of mobile element IS1, shown to be active, from the genome of P1vir, a coliphage frequently used in genome engineering procedures. The engineered, IS-free coliphage, P1virdeltaIS, displayed normal plaque morphology, phage titre, burst size and capacity for generalized transduction. When performing head-to-head competition experiments, P1vir could not outperform P1virdeltaIS, further indicating that the specific copy of IS1 plays no direct role in lytic replication. Overall, P1virdeltaIS provides a genome engineering vehicle free of IS contamination, and BRED is likely to serve as a generally applicable tool for engineering bacteriophage genomes in a wide range of taxa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.